Cover Image

Ipilimumab-Induced Neutropenia in Melanoma

Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related. Severe hematological toxicity is rare. We report a case of severe neutropenia followin...

Full description

Saved in:
Bibliographic Details
Main Authors: Makiko Ban-Hoefen MD (Author), Richard Burack MD (Author), Lynn Sievert NP (Author), Deepak Sahasrabudhe MD (Author)
Format: Book
Published: SAGE Publishing, 2016-08-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_94076e5cf7b64fdca7819f6dc17f5227
042 |a dc 
100 1 0 |a Makiko Ban-Hoefen MD  |e author 
700 1 0 |a Richard Burack MD  |e author 
700 1 0 |a Lynn Sievert NP  |e author 
700 1 0 |a Deepak Sahasrabudhe MD  |e author 
245 0 0 |a Ipilimumab-Induced Neutropenia in Melanoma 
260 |b SAGE Publishing,   |c 2016-08-01T00:00:00Z. 
500 |a 2324-7096 
500 |a 10.1177/2324709616661835 
520 |a Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related. Severe hematological toxicity is rare. We report a case of severe neutropenia following ipilimumab therapy that fully resolved after the administration of prednisone, cyclosporine, and anti-thymocyte globulin therapies. 
546 |a EN 
690 |a Medicine (General) 
690 |a R5-920 
690 |a Pathology 
690 |a RB1-214 
655 7 |a article  |2 local 
786 0 |n Journal of Investigative Medicine High Impact Case Reports, Vol 4 (2016) 
787 0 |n https://doi.org/10.1177/2324709616661835 
787 0 |n https://doaj.org/toc/2324-7096 
856 4 1 |u https://doaj.org/article/94076e5cf7b64fdca7819f6dc17f5227  |z Connect to this object online. 

Similar Items